Vilobelimab

Summary

Vilobelimab (CHEMBL2109636) is a phase-3 clinical-stage antibody (ATC L04AJ10); indicated across 11 conditions including pyoderma and granulomatosis with polyangiitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• ATC class: L04AJ10
• Indications: 11 conditions
• Clinical trials: 10

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109636
Name	Vilobelimab
Type	Antibody
Max phase	3
ATC	L04AJ10

Also known as: CACP 29, CACP29, IFX-1, Vilobelimab, VILOBELIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pyoderma	3	MONDO:0002922	HP:0000999
granulomatosis with polyangiitis	2	MONDO:0012105	EFO:0005297
toxic shock syndrome	2	MONDO:0001881	EFO:0006834
hidradenitis suppurativa	2	MONDO:0006559	EFO:1000710
microscopic polyangiitis	2	MONDO:0019124	EFO:1000784
severe acute respiratory syndrome	2	MONDO:0005091	MONDO:0100096
skin carcinoma	2	MONDO:0002656	EFO:0009259
pyoderma gangrenosum	1	MONDO:0018824	EFO:0006835
anti-neutrophil cytoplasmic antibody-associated vasculitis	1	MONDO:0015492	MONDO:0015492

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE2	7
PHASE2/PHASE3	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04333420	PHASE2/PHASE3	COMPLETED	Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia
NCT05964413	PHASE3	TERMINATED	Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
NCT02246595	PHASE2	COMPLETED	Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
NCT02866825	PHASE2	COMPLETED	Studying Complement Inhibition in Complex Cardiac Surgery
NCT03001622	PHASE2	COMPLETED	Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa
NCT03487276	PHASE2	COMPLETED	Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT03895801	PHASE2	COMPLETED	Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
NCT03971643	PHASE2	COMPLETED	Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
NCT04812535	PHASE2	TERMINATED	Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.
NCT01319903	PHASE1	COMPLETED	Clinical Assessment of Safety and Tolerability of the New Monoclonal Humanized Antibody CaCP29

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).